Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma

Abstract

This study aimed to clarify epigenetic and genetic alterations that occur during renal carcinogenesis. The original method includes chromosome 3 specific NotI-microarrays containing 180 NotI-clones associated with 188 genes for hybridization with 23 paired normal/tumor DNA samples of primary clear cell renal cell carcinomas (ccRCC). Twenty-two genes showed methylation and/or deletion in 17–57% of tumors. These genes include tumor suppressors or candidates (VHL, CTDSPL, LRRC3B, ALDH1L1, and EPHB1) and genes that were not previously considered as cancer-associated (e.g., LRRN1, GORASP1, FGD5, and PLCL2). Bisulfite sequencing analysis confirmed methylation as a frequent event in ccRCC. A set of six markers (NKIRAS1/RPL15, LRRN1, LRRC3B, CTDSPL, GORASP1/TTC21A, and VHL) was suggested for ccRCC detection in renal biopsies. The mRNA level decrease was shown for 6 NotI-associated genes in ccRCC using quantitative PCR: LRRN1, GORASP1, FOXP1, FGD5, PLCL2, and ALDH1L1. The majority of examined genes showed distinct expression profiles in ccRCC and papillary RCC. The strongest extent and frequency of downregulation were shown for ALDH1L1 gene both in ccRCC and papillary RCC. Moreover, the extent of ALDH1L1 mRNA level decrease was more pronounced in both histological types of RCC stage III compared with stages I and II (P = 0.03). The same was observed for FGD5 gene in ccRCC (P < 0.06). Dedicated to thememory of Eugene R. Zabarovsky

WITHDRAWN: Correlation between FOXP1 and ER/PR expression in endometrial carcinoma

“…It plays an important role in the regulation of B cell development and monocyte differentiation, and participates in cardiac valve morphodifferentiation and lung development [4]. Numerous studies have shown that the expression level of FOXP1 shows a marked change in tumor tissues, being lower in renal, breast, ovarian, lung and prostate cancers than in normal tissues [5][6][7][8][9][10], but is increased in malignant tumors such as lymphoma, which indicates that FOXP1 may have other roles except as an anti-oncogene [11][12][13].…”

PPM1M and PRICKLE2 are potential tumor suppressor genes in human clear-cell renal cell carcinoma

“…Clear-cell renal cell carcinoma (ccRCC) accounts 70-80 % of all renal cancer cases and is characterized by chemo-and radio-resistance [1]. According to the NotI-microarrays, the PPM1M and PRICKLE2 genes showed the presence of methylation/deletion more than in 20 % of ccRCC tumor samples [2]. We performed an analysis of the GEO data base for the PPM1M and PRICKLE2 genes (http://www.…”

“…This corresponds to a low percentage of methylation/deletion changes in the microarray analysis of these genes [2].…”

Renal cell carcinoma: Review of etiology, pathophysiology and risk factors

“…Up to 10% of RCC patients present with characteristic clinical symptoms consisting of hematuria, lateral dorsal or flank pain and palpable abdominal mass. Over 60% of RCC are detected incidentally in routine ultrasound examination 7 . Despite the advances in diagnosis, especially improved imaging techniques, about 20-30% of all patients are diagnosed with metastatic disease.…”